Active Ingredient History
Ocrelizumab, sold under the brand name Ocrevus, is a medication used for the treatment of multiple sclerosis (MS). It is a humanized anti-CD20 monoclonal antibody. It targets CD20 marker on B lymphocytes and is an immunosuppressive drug. Ocrelizumab binds to an epitope that overlaps with the epitope to which rituximab binds. Wikipedia
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Arthritis, Rheumatoid (Phase 3)
Autoimmune Diseases (Phase 2)
Central Nervous System Diseases (Phase 4)
Lupus Erythematosus, Systemic (Phase 3)
Lupus Nephritis (Phase 3)
Lymphoma, Large B-Cell, Diffuse (Phase 4)
Lymphoma, Non-Hodgkin (Phase 1/Phase 2)
Multiple Sclerosis (Phase 4)
Recurrence (Phase 3)
Schizophrenia (Phase 1/Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
